We introduce Jonas Ekstrand—a scientist, entrepreneur, and ecosystem builder with more than three decades of experience in life science. From pioneering cancer research to leading SwedenBIO and co-founding Nordic Life Science Days, he has dedicated his career to advancing collaboration and strengthening the Nordic region’s global presence. He shares his reflections on building a multifaceted career, the mentors who inspired him, and the untapped potential of the Nordic life science ecosystem.

Cell & Gene Therapy Insights recently published an article by Helena Strigård, Founder of Ventures Accelerated, exploring the untapped medical and market potential in women’s health and the transformative role of AI and precision medicine. 

In conversations with Roger Lias and Maria Lundius, we found that the Nordics are a strategic entry point into Europe for life sciences, combining faster clinical trials, high-quality data, strong biomanufacturing capacity, and a uniquely collaborative culture that accelerates development and de-risks scale-up.

FDA’s recent move to waive requirements for clinical efficacy studies (CESs) to approve of monoclonal antibody biosimilars certainly redefines the regulatory landscape for biologic drugs. This decision opens the door to new strategies and players in the biosimilars sector. The impact of FDA’s new approval policy is thus potentially very significant, promising lower development costs, faster patient access, and certainly enhanced competition, particularly benefiting generic and biotech firms. 

Learn how SANC is transforming neurosurgery across Africa through visionary collaboration — and support the mission at the Impact Days gala on December 11 in Stockholm, featuring global leaders turning bold ideas into lasting impact.

Facing $300 billion in lost revenue from expiring patents, Big Pharma is turning to M&A to secure future growth — triggering a wave of dealmaking across the Biotech sector. Major players are snapping up companies in high-value areas like oncology, neuroscience, and AI-enabled platforms. While this creates valuable exit opportunities for mature Biotechs, early-stage innovators may struggle as buyers focus on de-risked assets. To stand out in this climate, Biotech firms need sharp, targeted partnering strategies.

We introduce Andreas Hallbert— a branding strategist working at the crossroads of design, business, and life science. He shares how simplicity, clarity, and strong visual storytelling help even small companies build trust, stand out, and communicate their innovation effectively.

Noviral, a frontrunner in preventive healthcare solutions, announced the appointment of Mattias Bodin as the company’s new interim Chief Executive Officer (CEO). With over 30 years of experience in the pharmaceutical and medical device industries, Mattias is poised to steer Noviral into its next phase of growth and innovation, while fully backed by Ventures Accelerated - a consortium of C-suite leaders in life sciences.

As the field of Advanced Therapy Medicinal Products (ATMPs) faces mounting regulatory, financial, and scientific pressures, companies are taking a moment to pause, recalibrate, and return to execution fundamentals. This article explores how collaboration, early-stage funding, and scalable innovation are essential to ensure the continued success of next-generation therapies like cell and gene treatments.

Diamyd Medical has received FDA Fast Track and Orphan Drug Designations for its precision medicine targeting early-stage Type 1 Diabetes, now in Phase 3 trials. As the FDA begins using AI tools like Elsa, companies must craft submissions that resonate with both human and machine reviewers.

While digital communication offers speed, efficiency, and global reach, it often lacks the depth, empathy, and serendipity of face-to-face interactions. In-person meetings foster trust, spark unexpected ideas, and remind us of the profoundly human elements that no screen can fully replicate.

The biopharmaceutical industry faces challenges in efficiently manufacturing monoclonal antibodies despite their medical success. A new study shows that magnetic separation technology could significantly improve production by reducing costs, increasing output, and streamlining processes.

New U.S. tariff threats on imported pharmaceuticals, particularly generics, could raise drug prices and disrupt global supply chains. While aimed at boosting domestic production, critics argue the move may have limited impact on branded drugs, risk trade tensions, and come with significant short-term costs and uncertain long-term benefits.

Political uncertainty and shifting U.S. policies—particularly on tariffs and government funding—are creating turbulence in the life science investment climate. While long-term fundamentals remain stable, investors are cautious, and smart companies are using this period to adapt strategies and prepare for a new economic reality.

“May you live in interesting times” is an English expression that is claimed to be a translation of a traditional Chinese curse. The expression is intentionally ironic: "interesting" times are usually times of trouble. There is much doubt about this saying actually originating in China. There can, however, be precious little doubt that we do live in “interesting times” right now.